In addition, it is important to note that most of the small molecule pathway inhibitors generated from these programs specifically focus on inhibiting SMO and do not exhibit efficacy against Hh/GLI-dependent cancers that develop from mutations occurring downstream of SMO or from GLI1/GLI2 overexpression. This evidence concerns the gene GLI1 and cancer.